PRELIMINARY AGENDA

(as of June 17, 2025)

WEDNESDAY, OCTOBER 29, 2025

| 09:00 – 10:35 | Session 1: RNA Delivery Innovation & Platforms |
|---------------|---|
| | Chair: TBA |
| 09:00 - 09:05 | Opening Remarks |
| 09:05 - 09:30 | Nucleic Acid Therapeutic Unlabeled Reporter Assay (NATURA): A novel platform for high-throughput quantification of NATs' functional delivery and potency Ernesto Guccione Principal Investigator, The Guccione Lab, Icahn School of Medicine at Mount Sinai , USA |
| 09:30 - 09:55 | Modeling and Modulating Antitumor Immunity with RNA nanoparticles in 3D-Bioprinted Tumoroids Ronit Satchi-Fainaro Director, Cancer Biology Research Center, and Director, TAU Kahn 3D BioPrinting Initiative, TAU, IL |
| 09:55 – 10:05 | Start-Up Presentation DELiveri: Massive throughput screens to identify conjugates that promote cell delivery of nucleic acid therapeutics Yaniv Erlich CEO and Co-Founder, Eleven Therapeutics, IL |
| 10:05 – 10:15 | Start-Up Presentation Improved Delivery of RNAs for Extra-Hepatic Delivery Ruben Postel CSO & Scientific Founder, Sapreme Technologies, The Netherlands |
| 10:15 – 10:35 | Coffee Break, Visit the Exhibition & Poster Viewing |
| 10:35 – 13:00 | Session 2: RNA Splicing Mechanisms in Cancer |
| | Chair: TBA |
| 10:35 – 11:00 | SRSF1-regulated alternative splicing controls on oncogenic circuit in pancreatic cancer Adrian Krainer St. Giles Foundation Professor, Cold Spring Harbor Laboratory, New York, USA |
| 11:00 – 11:25 | Splicing dysregulation: Hallmark and therapeutic opportunity in cancer Claudio Sette Principal Investigator, Catholic University of the Sacred Heart, School of Medicine, Italy |

| | T |
|---------------|---|
| 11:25 – 11:50 | Pseudoexon activation as a therapeutic approach Brage Storstein Andresen Head of Research, Brage Storstein Andresen Lab, University of Southern Denmark |
| 11:50 – 12:15 | Selected Talk |
| 12:15 – 12:40 | Selected Talk |
| 12:40 – 12:50 | Selected Talk |
| 12:50 – 13:00 | Selected Talk |
| 13:00 – 14:00 | Lunch Break, Visit the Exhibition & Poster Viewing |
| 14:00 – 15:45 | Session 3: Novel Therapeutic Applications of RNA Technology: Part 1 |
| | Chair: TBA |
| 14:00 – 14:05 | Opening Remarks |
| | Dual-function oligonucleotide strategies for immunotherapy of acute myeloid leukemia Marcin Kortylewski Principal Investigator, The Kortylewski Lab, City of Hope , USA |
| 14:30 – 14:55 | Therapeutic approaches for HNRNPH2-Related Neurodevelopmental Disorder, an ultra-rare neurogenetic disorder Christopher Ricupero Assistant Professor, Columbia University Irving Medical Center, USA |
| | Working with patient communities to develop ASO based therapies Yael Weiss Founder & CEO, Mahzi Therapeutics, USA |
| 15:20 – 15:45 | Targeting RNA splicing in immune-oncology and beyond Thomas Westbrook Executive Director, Therapeutic Innovation Center, Baylor College of Medicine, USA |
| 15:45 – 16:15 | Coffee Break, Visit the Exhibition & Poster Viewing |
| 16:15 – 18:45 | Session 4: Novel Therapeutic Applications of RNA Technology: Part 2 |
| | Start-Up Presentation A transformative RNA (ASOs) based company for the treatment of pulmonary diseases Gili Hart CEO, SpliSense, IL |
| 16:25 – 16:35 | Start-Up Presentation Enabling Precision Medicine: From Liquid Biopsy to Antigen Discovery with Next-Gen Technologies Massimiliano Clamer Chairman & Founder, Immagina Biotechnology, Italy |

| 16:35 – 17:00 | Developing RNA based approaches for the treatment of Pompe Disease and neurodegenerative conditions Emanuele Buratti Group Leader, Molecular Pathology Lab, ICGEB, Italy |
|---------------|--|
| | Industry Panel Discussion: Shaping the Future of RNA Therapeutics: Innovation, Investment, and Impact Panelists: Yael Gruenbaum Cohen, aMoon Alpha, IL Michelle Lynn Hall, Associate Vice President, Eli Lilly and Company, USA Yaniv Erlich, CEO and Co-Founder, Eleven Therapeutics, IL |
| 17:45 – 18:45 | Poster Session |

THURSDAY, OCTOBER 30, 2025

| 08:30 - 10:20 | Session 5: Novel Therapeutic Applications of RNA Technology: Part 3 |
|---------------|--|
| | Chair: TBA |
| 08:30 - 08:35 | Opening Remarks |
| 08:35 - 09:00 | Targeting noncoding elements to boost haploinsufficient gene expression lgor Ulitsky Principal Investigator, Ulitsky Lab, Weizmann Institute of Science, IL |
| 09:00 - 09:25 | Small and long non-coding RNA transforming cell fates in the brain Anna Krichevsky Brigham and Women's Hospital, and Harvard Medical School, USA |
| 09:25 - 09:50 | Exploiting the dark genome to target drug-tolerant cells and improve anticancer immune therapies Eleonora Leucci Principal Investigator - RNA Cancer Biology Lab, KU Leuven, Belgium |
| 09:50 - 10:00 | Start-Up Presentation Cell-free RNA as a Mediator of Inflammation: New Paradigms for Therapeutic Intervention James Posada Chief Executive Officer, Resolve Therapeutics, USA |
| 10:00 – 10:10 | Start-Up Presentation Bispecific siRNA to reduce Cardiometabolic Risk Michael Khan Chief Executive Officer, Argonaute RNA, UK |
| 10:10 – 10:20 | Selected Talk |
| 10:20 - 10:40 | Coffee Break, Visit the Exhibition & Poster Viewing |

| 10:40 – 13:00 | Session 6: Innovations in Tumor Targeting and Cancer Immunotherapy |
|---------------|---|
| | Using RNA |
| | Chair: TBA |
| 10:40 - 10:45 | Opening Remarks |
| 10:45 – 11:10 | Rewriting the Message: RNA Splice Disruption Unmasks New Cancer Immunotherapy Targets Michal Lotem Head of The Hadassah Cancer Research Institute (HCRI), Hadassah Hebrew University Medical Center, IL |
| 11:10 – 11:35 | Aberrantly spliced cancer proteoforms: If you can't beat them, eat them! Andrei Thomas-Tikhonenko Director of Experimental Pathology, Children's Hospital of Philadelphia, USA |
| 11:35 – 12:00 | Targeting RNA processing to induce neoantigen in cancer cells Rotem Karni Principal Investigator, Hebrew University-Hadassah Medical School, IL and University of Pennsylvania, USA |
| 12:00 – 12:25 | Translation Dysregulation in Cancer as a Source for Targetable Antigens Yardena Samuels Director, Moross Integrated Cancer Center, Samuels Lab, Weizmann Institute of Science, IL |
| 12:25 – 12:50 | A novel regulatory circuit required for tumor angiogenesis and cancer growth Claudia Ghigna Scientist, Institute of Molecular Genetics, Italy |
| 12:50 – 13:00 | Selected Talk |
| 13:00 – 14:00 | Lunch Break, Visit the Exhibition & Poster Viewing |
| 14:00 – 15:20 | Session 7: RNA Regulation & Translation in Cancer Biology |
| | Chair: TBA |
| 14:00 – 14:05 | Opening Remarks |
| 14:05 – 14:30 | RNA-binding proteins in melanoma progression Fátima Gebauer President of the RNA Society and Principal Investigator, Center for Genomic Regulation (CRG) , Spain |
| 14:30 – 14:55 | Exploiting RNA translation control to fight cancer resistance Caroline Robert Head of Dermatology, Gustave Roussy Institute, France |
| 14:55 – 15:20 | Ultra-conserved poison exons in SR protein splicing regulator genes: Do these operate as tumour suppressors or protect the functions of specific cell types? David Elliott Principal Investigator, Newcastle University, UK |
| 15:20 – 15:45 | Coffee Break, Visit the Exhibition & Poster Viewing |

| 15:45 – 16:40 | Session 8: RNA Regulation & Translation in Cancer Biology (cont.) |
|---------------|--|
| 15:45 – 15:55 | Start-Up Presentation Targeting m6A-RNA Biology IN FTO-Dependent Cancers |
| | Amir Mor |
| | CSO, RNAble , IL |
| 15:55 – 16:20 | Breast cancer transcriptomics at the bulk, single cell and spatial levels |
| | Carlos Caldas |
| | Honorary Consultant in Medical Oncology, University of Cambridge , UK |
| 16:20 - 16:30 | Selected Talk |
| 16:30 - 16:40 | Selected Talk |

FRIDAY, OCTOBER 31, 2025

| 09:00 – 10:20 | Session 9: Computational & Al Applications in RNA Therapeutics |
|---------------|--|
| | Chair: TBA |
| 09:00 - 09:05 | Opening Remarks |
| 09:05 - 09:30 | Al-Driven Design: Unlocking Novel Mechanisms in RNA Therapeutics |
| | Tamar Grossman |
| | CEO, La Jolla Labs, USA |
| 09:30 - 09:55 | miRNA-based logic circuits encoded on self-amplifying RNA for highly specific cancer |
| | cell classification |
| | Ron Weiss |
| | Principal Investigator, The Weiss Lab, Massachusetts Institute of Technology, |
| | USA |
| 09:55 - 10:20 | Harnessing RNA-Driven Intelligence to Revolutionize Personalized Cancer Therapy |
| | Aron Popovtzer |
| | Director of the Sharett Institute of Oncology, Hadassah Medical Center, IL |
| 10:20 – 10:45 | Coffee Break, Visit the Exhibition & Poster Viewing |
| 10:45 – 12:30 | Session 10: Computational & Al Applications in RNA Therapeutics (cont.) |
| 10:45 – 11:10 | Decoding Cancer Complexity: Machine Learning and Transcriptomic Signatures |
| | Shai Rosenberg |
| | Head of the Computational Medicine Service, Hadassah Hebrew University |
| 11:10 – 11:20 | Medical Center, IL Start-Up Presentation |
| 11.10 - 11.20 | Utilizing Machine Learning to Unlock RNA Delivery |
| | Yogev Debbi |
| | Co-Founder & CEO, Mana.bio, IL |
| 11:20 – 11:30 | Selected Talk |

| 11:30 – 11:40 | Selected Talk |
|---------------|--|
| 11:40 – 12:30 | Concluding Remarks & Symposium Closure |
| 12:30 – 13:00 | Lunch |